Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical released its third‑quarter 2026 financial results, covering both the quarter and the nine‑month period ending September 30, 2026. The company disclosed substantial expense reductions and reiterated its expectation of returning to profitability in calendar year 2027. The official release, echoed by Marketscreener’s earnings summary, presented the updated balance sheet and income figures while emphasizing the firm’s confidence in meeting the 2027 profit target. No specific profit amount was disclosed.

The filing also noted that the company continues to pursue its pipeline without altering major development timelines. Later reporting supplied details on operational actions. Endpoints News reported a plan to lay off roughly one‑fifth of Ultragenyx’s staff and to discard a gene‑therapy candidate for Wilson disease. Fierce Biotech added that the firm is cutting R&D spending by roughly half and eliminating certain assets to streamline its portfolio.

TradingView highlighted recent FDA approvals and the company’s decision to exit specific clinical studies, framing these moves as consistent with the 2027 profit ambition. The juxtaposition of regulatory wins and aggressive cost cuts creates a dual narrative. TradingView’s emphasis on FDA approvals contrasts with the focus of Endpoints News and Fierce Biotech on workforce reductions and reduced R&D spend, underscoring a balancing act between growth and profitability. Ultragenyx’s current trajectory, as outlined in its own release, keeps the 2027 profit goal in view while the announced expense reductions take effect.